Ivo Boskoski, MD, PhD is an expert in Medical imaging at Agostino Gemelli University Polyclinic (Italy). As of October 2026, ScienceLeadR ranks Ivo Boskoski in the top 1% of experts worldwide for Endoscopy, Obesity and Overweight. Ivo Boskoski has authored 459 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 9 of them ongoing. SLR score: 1,719 (community average: 125). How the SLR is computed.

LeadR Profile

Ivo Boskoski, MD, PhD Agostino Gemelli University Polyclinic Italy
1 719 ScienceLeadR Reputation 1719
Network Map

Medical imaging

Subspecialties: Gastroenterology - Surgery - Hepatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

I am a Gastroenterologist with over 20 years of experience in advanced endoscopy, academic teaching, and clinical research. After graduating in Medicine from the University of Perugia (2005), I completed my residency in Gastroenterology at Campus Bio-Medico University of Rome (2009) and earned a PhD in Endoscopic Treatment of Obesity at the Catholic University of Rome (2013).


Currently, I serve as Associate Professor of Gastroenterology at the Catholic University of Rome and as Consultant Gastroenterologist at Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

My clinical and research focus includes:


Biliopancreatic endoscopy (ERCP) and cholangioscopy

Management of biliopancreatic complications and malignancies

Endoscopic treatment of chronic pancreatitis and postoperative complications

Bariatric endoscopy (ESG, bypass revisions, treatment of complications)

Regenerative endoscopy and innovative therapeutic approaches


I am passionate about education and innovation in endoscopy. Since 2009, I have been an Instructor and Faculty Member at the European Endoscopy Training Center (EETC) and IRCAD France, and I co-invented the Boškoski-Costamagna ERCP Training Model, widely used for hands-on training worldwide.


I also serve as Secretary and Advisory Board Member of the Centre for Endoscopic Research Therapeutics and Training (CERTT), and I was a Governing Board Member of the European Society of Gastrointestinal Endoscopy (ESGE) for the 2022-2025 term.


Author of numerous peer-reviewed publications, book chapters, and abstracts, I regularly lecture at national and international conferences and participate in live endoscopy workshops.

Organizations

Career arc: 2007 - 2026

Source: PubMed

Università Cattolica del Sacro Cuore di Roma

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 459

Citations

Citations: 3 723 1st author: 53 Last author: 77 Unique author: 4


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
3D bioprinting of stromal vascular fraction enriched with MXenes for enhanced intestinal regeneration.
PMID 42612693 — cells, bioprinting, biomedical engineering, tissue engineering, therapeutics
Biofabrication20260
Commentary.
PMID 42628542 — endoscopy
Endoscopy20260
Advanced cannulation techniques vs early EUS-BD in case of difficult biliary cannulation in patients with DMBO: an international propensity score-matched analysis.
PMID 42572882 — cholangiopancreatography, endoscopic retrograde, gastroenterology, jaundice, propensity score, pancreas
Am J Gastroenterol20260
Endoscopic Gastric Mega-plication (MEGA) for the Primary Treatment of Obesity: "A European Multicenter Retrospective Cohort Study, 6-month Outcomes".
PMID 42474954 — cohort studies, drug-related side effects and adverse reactions, sutures, obesity, therapeutics
Obes Surg20260
Safety Framework for Gastric Mucosal Ablation (GMA) Using Hybrid Argon Plasma Coagulation (hAPC): International Expert Consensus.
PMID 42142234 — safety, argon plasma coagulation, therapeutics, mucous membrane, plasma
Obes Surg20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

N/A 17
Phase 4 2
Phase 1 1

By status:

Recruiting 8
Completed 6
Unknown 3
Not yet recruiting 2
Enrolling by invitation 1

By type:

Interventional 15
Observational 5

By Monocentric/Multicentric:

monocentric 13
multicentric2to4 5
multicentric5to9 1
multicentricup10 1

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Endoscopic Injection of Autologous Fat Derived Cells (SVF) for Adults With Refractory Gastroesophageal Reflux Disease (GERD) (The GERD REVIVE Pilot Study)
NCT07638423 — injections, pilot projects, cells, pilots, safety, point-of-care systems, esophagogastric junction, digestion, endoscopy, therapeutics, tissues, gastroesophageal reflux, needles, adipose tissue
N/ANot yet recruiting2026
Study Evaluating the Safety and Feasibility of Endoscopic Duodenal Injections of Autologous Mesenchymal Stem Cells
NCT07344324 — diabetes mellitus, injections, pilot projects, cells, pilots, safety, insulin, microscopy, electron, scanning transmission, deep sedation, stem cells, mesenchymal stem cells, biopsy, obesity, therapeutics, tissues, needles, adipose tissue, diabetes mellitus, type 2
N/ANot yet recruiting2026
Endoscopic Injection of Autologous Activated and Emulsified Fat in Chronic Fistulas of the Gastrointestinal Tract and Pelvic Organs
NCT06930079 — injections, cells, quality of life, fistula, microscopy, electron, scanning transmission, communication, gastrointestinal tract, therapeutics, tissues, adipose tissue
N/ARecruiting2025
Effect of proton pump inhibitors on the structural integrity of endoscopic sleeve gastroplasty a single centre open label randomized controlled pilot clinical trial
2024-517679-18-00 — gastroplasty, pilots, proton pump inhibitors, obesity, proton pumps
Phase 4Recruiting2024
The ESG Integrity Study Effect of Proton Pump Inhibitors on the Structural Integrity of Endoscopic Sleeve Gastroplasty
NCT06283381 — gastroplasty, pilots, administration, oral, esomeprazole, tablets, proton pump inhibitors, obesity, proton pumps
Phase 4Recruiting2024

LeadR Networks

Main global connection map